Tci Wealth Advisors, Inc. Veracyte, Inc. Transaction History

Tci Wealth Advisors, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$20.58 - $27.89 $20 - $27	1 Added 0.51%	198 $4,000
Q4 2022 Feb 06, 2023	BUY	$15.31 - $29.94 $3,016 - $5,898	197 New	197 $4,000
Q2 2022 Jul 19, 2022	SELL	$15.45 - $29.52 $5,283 - $10,095	-342 Closed	0 $0
Q1 2022 Apr 29, 2022	BUY	$21.94 - $42.51 $877 - $1,700	40 Added 13.25%	342 $9,000
Q4 2021 Jan 24, 2022	SELL	$36.09 - $53.79 $108 - $161	-3 Reduced 0.98%	302 $12,000
Q3 2021 Oct 29, 2021	BUY	$35.62 - $52.97 $4,096 - $6,091	115 Added 60.53%	305 $14,000
Q2 2021 Aug 02, 2021	SELL	$32.94 - $56.62 $263 - $452	-8 Reduced 4.04%	190 $8,000
Q1 2021 Apr 29, 2021	BUY	$44.47 - $81.38 $4,802 - $8,789	108 Added 120.0%	198 $11,000
Q1 2020 Apr 14, 2020	SELL	$16.13 - $30.17 $677 - $1,267	-42 Reduced 31.82%	90 $2,000
Q2 2019 Jul 23, 2019	BUY	$22.1 - $28.56 $928 - $1,199	42 Added 46.67%	132 $4,000
Q1 2019 Apr 11, 2019	BUY	$12.0 - $25.76 $384 - $824	32 Added 55.17%	90 $2,000
Q4 2018 Jan 17, 2019	BUY	$9.15 - $14.85 $530 - $861	58 New	58 $1,000

320

80.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.